For the quarter ended June 2025, Adaptive Biotechnologies (ADPT) reported revenue of $58.88 million, up 36.3% over the same period last year. EPS came in at -$0.17, compared to -$0.26 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $49.7 million, representing a surprise of +18.47%. The company delivered an EPS surprise of +29.17%, with the consensus EPS estimate being -$0.24.While investors scrutinize revenue and earnings changes year-over-year and how they compare w ...

Group 1 - Adaptive Biotechnologies reported a quarterly loss of $0.17 per share, better than the Zacks Consensus Estimate of a loss of $0.24, and improved from a loss of $0.26 per share a year ago, resulting in an earnings surprise of +29.17% [1] - The company achieved revenues of $58.88 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 18.47%, and up from $43.19 million in the same quarter last year [2] - Adaptive Biotechnologies shares have increased approximately 82% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.6% [3] Group 2 - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend of estimate revisions for Adaptive Biotechnologies was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.21 on revenues of $56.63 million, and for the current fiscal year, it is -$0.87 on revenues of $218.28 million [7] Group 3 - The outlook for the Medical - Biomedical and Genetics industry, where Adaptive Biotechnologies operates, is currently in the bottom 43% of over 250 Zacks industries, which may impact stock performance [8]

Adaptive Biotechnologies (ADPT) Q2 2025 Earnings Call August 05, 2025 04:30 PM ET Speaker0Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Second Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone.You will then hear an automated message advising your ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) | Washington | 27-090 ...

Second Quarter 2025 Earnings Conference Call Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation ("we," "us," "our," "Adaptive" or the "Company") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation of an ...

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results EXHIBIT 99.1 SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2025. "We delivered an outstanding second quarter, achieving profitability in o ...

SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2025. “We delivered an outstanding second quarter, achieving profitability in our MRD business with accelerating top- and bottom-line growth,” said Chad Robins, c ...

Core Insights - Adaptive Biotechnologies Corporation will report its financial results for Q2 2025 on August 5, 2025, after market close [1] - A conference call will follow the financial results announcement, starting at 1:30 p.m. Pacific Time [1] Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on utilizing the adaptive immune system for disease diagnosis and treatment [3] - The company aims to decode the adaptive immune system's genetics to enhance medical capabilities in diagnosing and treating diseases [3] - Its proprietary immune medicine platform is designed to provide scalable, precise, and rapid insights into the adaptive immune system [3] - The company operates in two business segments: Minimal Residual Disease (MRD) and Immune Medicine, targeting diseases such as cancer and autoimmune disorders [3] - The goal is to develop and commercialize immune-driven clinical products tailored to individual patients [3]

Company Performance - Adaptive Biotechnologies (ADPT) has gained approximately 96.8% year-to-date, significantly outperforming the average return of -3.1% for Medical companies [4] - The Zacks Consensus Estimate for ADPT's full-year earnings has increased by 5.5% over the past 90 days, indicating improved analyst sentiment and a stronger earnings outlook [4] - Adaptive Biotechnologies holds a Zacks Rank of 2 (Buy), suggesting it has favorable characteristics to outperform the market in the near term [3] Industry Context - Adaptive Biotechnologies is part of the Medical - Biomedical and Genetics industry, which consists of 495 companies and currently ranks 85 in the Zacks Industry Rank [6] - The average performance of the Medical - Biomedical and Genetics industry has seen a loss of 1.1% year-to-date, highlighting ADPT's superior performance within its industry [6] - Another company in the same sector, Anavex Life Sciences (AVXL), has also shown strong performance with a year-to-date increase of 0.5% and a Zacks Rank of 2 (Buy) [5][6]

Core Viewpoint - The integration of Adaptive Biotechnologies' clonoSEQ test for measurable residual disease (MRD) assessment into Flatiron Health's OncoEMR platform enhances access to MRD testing for clinicians, improving treatment decision-making for blood cancer patients [1][2][3][4]. Company Overview - Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment [8][9]. - Flatiron Health is a healthtech company dedicated to advancing point-of-care solutions in oncology, utilizing data to improve cancer care [10]. Product Integration - The clonoSEQ test will be integrated into OncoEMR, allowing over 4,500 clinicians across 1,000 community-based cancer care locations in the U.S. to order and review MRD testing results directly within the EMR [2][4]. - This integration aims to streamline access to MRD data, enabling community clinicians to make more informed treatment decisions for blood cancer patients [3][4]. Clinical Significance - clonoSEQ is the first FDA-cleared in vitro diagnostic test for detecting and tracking MRD in multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, among other lymphoid cancers [5][6]. - The test can detect one cancer cell in one million healthy cells, providing precise monitoring of MRD over time, which is crucial for predicting patient outcomes and informing treatment strategies [6][7]. Market Impact - The integration of clonoSEQ into OncoEMR is expected to enhance the efficiency of testing workflows and provide real-time insights into patients' disease status, ultimately improving patient care in community oncology settings [2][4][11].